FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089421034> ?p ?o ?g. }

• W3089421034 endingPage "100553" @default.
• W3089421034 startingPage "100553" @default.
• W3089421034 abstract "Interleukin-6 signal blockade showed preliminary beneficial effects in treating inflammatory response against SARS-CoV-2 leading to severe respiratory distress. Herein we describe the outcomes of off-label intravenous use of Sarilumab in severe SARS-CoV-2-related pneumonia.53 patients with SARS-CoV-2 severe pneumonia received intravenous Sarilumab; pulmonary function improvement or Intensive Care Unit (ICU) admission rate in medical wards, live discharge rate in ICU treated patients and safety profile were recorded. Sarilumab 400 mg was administered intravenously on day 1, with eventual additional infusion based on clinical judgement, and patients were followed for at least 14 days, unless previously discharged or dead.Of the 53 SARS-CoV-2pos patients receiving Sarilumab, 39(73·6%) were treated in medical wards [66·7% with a single infusion; median PaO2/FiO2:146(IQR:120-212)] while 14(26·4%) in ICU [92·6% with a second infusion; median PaO2/FiO2: 112(IQR:100-141.5)].Within the medical wards, 7(17·9%) required ICU admission, 4 of whom were re-admitted to the ward within 5-8 days. At 19 days median follow-up, 89·7% of medical inpatients significantly improved (46·1% after 24 h, 61·5% after 3 days), 70·6% were discharged from the hospital and 85·7% no longer needed oxygen therapy. Within patients receiving Sarilumab in ICU, 64·2% were discharged from ICU to the ward and 35·8% were still alive at the last follow-up. Overall mortality rate was 5·7%.IL-6R inhibition appears to be a potential treatment strategy for severe SARS-CoV-2 pneumonia and intravenous Sarilumab seems a promising treatment approach showing, in the short term, an important clinical outcome and good safety." @default.
• W3089421034 created "2020-10-08" @default.
• W3089421034 creator A5001052603 @default.
• W3089421034 creator A5007707130 @default.
• W3089421034 creator A5008032415 @default.
• W3089421034 creator A5008500196 @default.
• W3089421034 creator A5013878143 @default.
• W3089421034 creator A5017672585 @default.
• W3089421034 creator A5019441565 @default.
• W3089421034 creator A5021461246 @default.
• W3089421034 creator A5023016168 @default.
• W3089421034 creator A5026147889 @default.
• W3089421034 creator A5026816687 @default.
• W3089421034 creator A5028014351 @default.
• W3089421034 creator A5031316687 @default.
• W3089421034 creator A5033125476 @default.
• W3089421034 creator A5037200438 @default.
• W3089421034 creator A5039554062 @default.
• W3089421034 creator A5040546928 @default.
• W3089421034 creator A5041049293 @default.
• W3089421034 creator A5042719796 @default.
• W3089421034 creator A5045989939 @default.
• W3089421034 creator A5048017448 @default.
• W3089421034 creator A5049298945 @default.
• W3089421034 creator A5053575436 @default.
• W3089421034 creator A5055735434 @default.
• W3089421034 creator A5057561190 @default.
• W3089421034 creator A5062383877 @default.
• W3089421034 creator A5062968410 @default.
• W3089421034 creator A5064352327 @default.
• W3089421034 creator A5067359355 @default.
• W3089421034 creator A5076471646 @default.
• W3089421034 creator A5078126497 @default.
• W3089421034 creator A5081015572 @default.
• W3089421034 creator A5082799069 @default.
• W3089421034 creator A5083163170 @default.
• W3089421034 creator A5084050042 @default.
• W3089421034 creator A5084427308 @default.
• W3089421034 creator A5085559353 @default.
• W3089421034 creator A5085647114 @default.
• W3089421034 creator A5086604902 @default.
• W3089421034 creator A5088006712 @default.
• W3089421034 creator A5090725835 @default.
• W3089421034 date "2020-10-01" @default.
• W3089421034 modified "2023-10-15" @default.
• W3089421034 title "Sarilumab use in severe SARS-CoV-2 pneumonia" @default.
• W3089421034 cites W2069019419 @default.
• W3089421034 cites W2093799856 @default.
• W3089421034 cites W2557016092 @default.
• W3089421034 cites W2796022095 @default.
• W3089421034 cites W3001118548 @default.
• W3089421034 cites W3001897055 @default.
• W3089421034 cites W3005403371 @default.
• W3089421034 cites W3007189521 @default.
• W3089421034 cites W3009639502 @default.
• W3089421034 cites W3012421327 @default.
• W3089421034 cites W3013671288 @default.
• W3089421034 cites W3014294089 @default.
• W3089421034 cites W3014663601 @default.
• W3089421034 cites W3016538467 @default.
• W3089421034 cites W3016987930 @default.
• W3089421034 cites W3022970339 @default.
• W3089421034 cites W3038241707 @default.
• W3089421034 cites W3038367105 @default.
• W3089421034 cites W3040955989 @default.
• W3089421034 cites W3165656738 @default.
• W3089421034 cites W4210642183 @default.
• W3089421034 doi "https://doi.org/10.1016/j.eclinm.2020.100553" @default.
• W3089421034 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7531933" @default.
• W3089421034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33043284" @default.
• W3089421034 hasPublicationYear "2020" @default.
• W3089421034 type Work @default.
• W3089421034 sameAs 3089421034 @default.
• W3089421034 citedByCount "61" @default.
• W3089421034 countsByYear W30894210342020 @default.
• W3089421034 countsByYear W30894210342021 @default.
• W3089421034 countsByYear W30894210342022 @default.
• W3089421034 countsByYear W30894210342023 @default.
• W3089421034 crossrefType "journal-article" @default.
• W3089421034 hasAuthorship W3089421034A5001052603 @default.
• W3089421034 hasAuthorship W3089421034A5007707130 @default.
• W3089421034 hasAuthorship W3089421034A5008032415 @default.
• W3089421034 hasAuthorship W3089421034A5008500196 @default.
• W3089421034 hasAuthorship W3089421034A5013878143 @default.
• W3089421034 hasAuthorship W3089421034A5017672585 @default.
• W3089421034 hasAuthorship W3089421034A5019441565 @default.
• W3089421034 hasAuthorship W3089421034A5021461246 @default.
• W3089421034 hasAuthorship W3089421034A5023016168 @default.
• W3089421034 hasAuthorship W3089421034A5026147889 @default.
• W3089421034 hasAuthorship W3089421034A5026816687 @default.
• W3089421034 hasAuthorship W3089421034A5028014351 @default.
• W3089421034 hasAuthorship W3089421034A5031316687 @default.
• W3089421034 hasAuthorship W3089421034A5033125476 @default.
• W3089421034 hasAuthorship W3089421034A5037200438 @default.
• W3089421034 hasAuthorship W3089421034A5039554062 @default.
• W3089421034 hasAuthorship W3089421034A5040546928 @default.
• W3089421034 hasAuthorship W3089421034A5041049293 @default.
• W3089421034 hasAuthorship W3089421034A5042719796 @default.

• next